Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Galderma Laboratories, L.P.
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions

Exclusion Criteria:

• Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis